Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132645 | 0.84 | EPHA2 (0.55) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5564929 | 0.82 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGCHEK2 | |
| SCHEMBL31071572 | 0.81 | GPR119 (0.53) | CHEK2GPR119 | |
| SCHEMBL30127280 | 0.81 | PDE4B (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGIRAK4 | |
| SCHEMBL17179600 | 0.79 | EPHA2 (0.52) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL664787 | 0.79 | EPHA2 (0.52) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31071546 | 0.79 | STS (0.53) | CHEK2GPR119SLC2A1ALOX5APFEN1 | |
| SCHEMBL7524902 | 0.79 | GPR119 (0.56) | CHEK2GPR119SLC2A1ALOX5APFEN1 | |
| SCHEMBL7526229 | 0.78 | GPR119 (0.51) | PIK3CDPIK3CACHEK2GPR119SLC2A1 | |
| SCHEMBL2287878 | 0.78 | GPR119 (0.50) | CHEK2GPR119SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | PIK3CD 294/4885PIK3CA 284/4885PIK3CB 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.